Showing posts with label Pathogens. Show all posts
Showing posts with label Pathogens. Show all posts

Thursday, 8 December 2011

Biofilms in drinking water and their role as reservoir for pathogens.

Biofilm Centre, University of Duisburg-Essen, Universitätsstraße 5, D-45141 Essen, Germany.

Most microorganisms on Earth live in various aggregates which are generally termed "biofilms". They are ubiquitous and represent the most successful form of life. They are the active agent in biofiltration and the carriers of the self-cleaning potential in soils, sediments and water. They are also common on surfaces in technical systems where they sometimes cause biofouling. In recent years it has become evident that biofilms in drinking water distribution networks can become transient or long-term habitats for hygienically relevant microorganisms. Important categories of these organisms include faecal indicator bacteria (e.g., Escherichia coli), obligate bacterial pathogens of faecal origin (e.g., Campylobacter spp.) opportunistic bacteria of environmental origin (e.g., Legionella spp., Pseudomonas aeruginosa), enteric viruses (e.g., adenoviruses, rotaviruses, noroviruses) and parasitic protozoa (e.g., Cryptosporidium parvum). These organisms can attach to preexisting biofilms, where they become integrated and survive for days to weeks or even longer, depending on the biology and ecology of the organism and the environmental conditions. There are indications that at least a part of the biofilm populations of pathogenic bacteria persists in a viable but non-culturable (VBNC) state and remains unnoticed by the methods appointed to their detection. Thus, biofilms in drinking water systems can serve as an environmental reservoir for pathogenic microorganisms and represent a potential source of water contamination, resulting in a potential health risk for humans if left unnoticed.

Copyright © 2011 Elsevier GmbH. All rights reserved.


View the original article here

Friday, 25 November 2011

In Vitro and In Vivo Profile of ACH-702, an Isothiazoloquinolone, against Bacterial Pathogens.

Authors: Pucci MJ, Podos SD, Thanassi JA, Leggio MJ, Bradbury BJ, Deshpande M ACH-702, a novel isothiazoloquinolone, was assessed for antibacterial activity against a panel of gram-positive and gram-negative clinical isolates and found to possess broad-spectrum activity, especially against antibiotic-resistant gram-positive strains including methicillin-resistant Staphylococcus aureus (MRSA). For gram-negative bacteria, ACH-702 showed exceptional potency against Haemophilus influenzae, Moraxella catarrhalis, and Neisseria sp., but was less active against members of the Enterobacteriaceae. Good antibacterial activity was also evident against several anaerobes as well as Legionella pneumophila and Mycoplasma pneumoniae. Excellent bactericidal activity was observed for ACH-702 against sev...

View the original article here

Monday, 21 November 2011

Adult outpatient experience of the 2009 H1N1 pandemic: Clinical course, pathogens, and evaluation of case definitions

Conclusions: Influenza A (H1N1) and human rhinovirus were the major pathogens responsible for respiratory disease. The 2009 H1N1 pandemic in Amsterdam followed a mild course. Test characteristics of 4 different clinical case definitions seemed comparable but rather useless. (Source: Journal of Infection)

View the original article here

Saturday, 7 May 2011

In Vitro and In Vivo Profile of ACH-702, an Isothiazoloquinolone, against Bacterial Pathogens.

Achillion Pharmaceuticals, New Haven, CT 06511.

ACH-702, a novel isothiazoloquinolone, was assessed for antibacterial activity against a panel of gram-positive and gram-negative clinical isolates and found to possess broad-spectrum activity, especially against antibiotic-resistant gram-positive strains including methicillin-resistant Staphylococcus aureus (MRSA). For gram-negative bacteria, ACH-702 showed exceptional potency against Haemophilus influenzae, Moraxella catarrhalis, and Neisseria sp., but was less active against members of the Enterobacteriaceae. Good antibacterial activity was also evident against several anaerobes as well as Legionella pneumophila and Mycoplasma pneumoniae. Excellent bactericidal activity was observed for ACH-702 against several bacterial pathogens in time-kill assays and postantibiotic effects (PAEs) >1 h were evident in both laboratory and clinical strains of staphylococci at 10x MIC, similar in most cases to those observed for moxifloxacin at the same MIC multiple. In vivo efficacy was demonstrated against S. aureus in murine sepsis and thigh infection models with decreases in CFU/thigh equal to or greater than those observed after vancomycin treatment. Macromolecular synthesis assays showed specific dose-dependent inhibition of DNA replication in staphylococci and biochemical analyses indicated potent dual inhibition of two essential DNA replication enzymes: DNA gyrase and topoisomerase IV. Additional biological data in support of an effective dual targeting mechanism-of-action include: low MIC values (=0.25 µg/ml) against staphylococcal strains with single mutations in both gyrA and grlA (parC), retention of good antibacterial activity (MICs =0.5 µg/ml) against staphylococcal strains with two mutations in both gyrA and grlA, and low frequencies for selection of higher-level resistance (<10(-10)). These promising initial data support further study of isothiazoloquinolones as potential clinical candidates.


View the original article here